1Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? [J]. Ann Oncol, 2006,17 (9) : 1347 -1359.
2Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabineversus intravenous fluorouracil p lus leucovorin as first2line treatment in 605 patients with metastatic colorectal cancer: results of arandomized phase III study [J]. J Clin Oncol,2001, 19 (8) :2282 -2292.
3de Gramont A, Boni C, Navarro M, et al. Oxalip latin/5FU /LV in adjuvant colon cancer: Updated efficacy results of theMOSA IC trial, including survival, with a median follow2up of six years [J]. JClin Oncol, 2007, 25 (18S) : a4007.
4Kuebler JP,Wieand HS, O' ConnellMJ, et al. Oxalip latin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer: results from NSABP C207 [J]. J Clin Oncol, 2007, 25 (16) : 2198 -2204.
5Kohne CH, van Cutsem E, Wils J, et al. Phase Ⅲ study of weekly highdose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986 [J]. J Clin Oncol, 2005, 23 (8) : 4856 -4865.
6Colucci G, Gebbia V, Paoletti G, et al. Phase Ⅲ randomized trial of FOLF IR I versus FOLFOX4 in the treatment of advanced colorectal cancer : A muhicenter study of the Gruppo Oncologico Dell'Italia Merid- ionale[Jl. J Clin Oncol, 2005, 23 (8): 4866-4875.
7Kulig J, Pop iela T, Richter P, et al. Evaluation of adjuvant chemo-therapy irinotecan + 5 -fluorouracil + leucovorine in advanced colorectal cancer[J]. Acta Chir Belg, 2007, 107 (3) : 297 -301.
8Moosmann N, Heinemann V. Cetuximab plus oxalip latin2based chemotherapy in the treatment of colorectal cancer[J]. Expert Rev Anticancer Ther, 2008, 8 (3) : 319 -329.
9Amado RG, Wolf M, Peeters M. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [ J ]. J Clin Oncol, 2008, 26 (10) : 1626 - 1634.
5Frei E 3rd.Clinical cancer research:an embattled species [J].Cancer,1982;50(10):1979
6Wilke H,Preusser P,Fink U,et al.Preoperative chemotherapy in locally advanced and nonresectable gastric cancer:a phase II study with etoposide,doxorubicin,and cisplatin [J].J Clin Oncol,1989;7(9):1318
7Kollmannsberger C,Quietzsch D,Haag C,et al.A phase Ⅱ study of paclitaxel,weekly,24-hour continous infusion 5-fluorouracil,folinic acid and cisplatin in patients with advanced gastric cancer [J].Br J Cancer,2000;83(4):458
8Lowy AM,Mansfield PF,Leach SD,et al.Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer [J].Ann Surg,1999;229(3):303
9Plukker JT,Mulder NH,Sleijfer DT,et al.Chemotherapy and surgery for locally advanced cancer of the cardia and fundus:phase Ⅱ study with methotrexate and 5-fluorouracil [J].Br J Surg,1991;78(8):955
10Kiyabu M,Leichman L,Chandrasoma P.Effects of preoperative chemotherapy on gastric adenocarcinomas.A morphologic study of 25 cases [J].Cancer,1992;70(9):2239
3Wen-Sy Tsai. Impact of chemotherapy-related prognostic factors on long- term survival in patients with stage III colorectal cancer after curative resection[J]. Int J Clin Oncol. DOI 10. 1007/s10147-011-0370-8.
4Bleiberg H. Oxaliplatin (L-OHP) : a new reality in colorectal cancer [J]. Br J Cancer,1998,77(Suppl 4) : 1 -3.
5Venook A P. Epidermal. growth factor receptor-targeted treatment for advanced colorectal carcinoma [ J ]. Cancer, 2005, 103 ( 2 ) : 2435 - 2446.
7Georgios V. Koukourakis. Targeted therapy with bevaeizumab ( Avas- tin) for metastatic colorectal cancer[ J]. Clin Transl Onco1,2011,13 : 710 -714.
8Hurwitz HI, Fehrenbacher L, Hainsworth JDet a1(2005 ) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer [ J]. J Clin Oncol, 2010,23: 3502 - 3508.
9Fisher GA,Kuo T,Cho CD. A phase II study of gefitinib in combina- tion with FOLFOX-4(IFOX) in patients with unresectable or metastat- ic colorectal cancer [ J ]. Proc "Am Soc Oncol, 2004, 22 ( 14 ) : 3514 -3516.
10Lockhart AC, C ropp GF, Berlin JD, et al. Phase I/pilot study of SU5416(semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer[ J]. Am JC lin On- co,1 2006,29(2) : 109 - 115.
